Effect of Initial Treatment Choice on 2-year Quality of Life in Patients with Low-risk Papillary Thyroid Microcarcinoma

<jats:title>Abstract</jats:title> <jats:sec> <jats:title>Context</jats:title> <jats:p>The long-term quality of life (QoL) in patients with low-risk papillary thyroid microcarcinoma (PTMC) underwent active surveillance (AS) and immediate surgery is unclear.</jats:p> </jats:sec> <jats:sec> <jats:title>Objective</jats:title> <jats:p>The aim of this study was to investigate the effect of initial treatment choice on 2-year QoL in patients with low-risk PTMC</jats:p> </jats:sec> <jats:sec> <jats:title>Design, Setting, and Participants</jats:title> <jats:p>We analyzed 2652 QoL surveys from 1055 subjects enrolled in ongoing multicenter prospective cohort study on active surveillance of PTMC, in which the median follow-up duration was 24.4 months.</jats:p> </jats:sec> <jats:sec> <jats:title>Major Outcome Measure</jats:title> <jats:p>We evaluated QoL of patients with low-risk PTMC according to their treatment modality using generalized estimating equation.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Six hundred and seventy-four subjects (male = 161; mean age = 48.8 ± 11.9 years) with low-risk PTMC chose AS while 381 subjects (male = 75; mean age = 45.7 ± 10.4 years) chose immediate surgery, including lobectomy/isthmusectomy (L/I) and total thyroidectomy (TT). Among the 817 subjects who completed baseline QoL surveys, 2-year QoL was good in order of AS (n = 500), L/I (n = 238), and TT (n = 79) groups after adjustment for age, sex, baseline tumor size, and baseline QoL scores. Among the 101 subjects who changed their treatment from AS to surgery during the follow-up period, 35 subjects who changed treatment due to disease progression had better QoL than 66 subjects who had no disease progression.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>This study identified QoL as a major issue in choosing an initial treatment of low-risk PTMC and highlighted the possibility of using AS as the primary treatment.</jats:p> </jats:sec>